close
Add to watchlist
Opexa Therapeutics Inc (OPXA)
Opexa Therapeutics, Inc. operates as a biopharmaceutical company, developing autologous cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS) and diabetes. These therapies are based on Opexa's proprietary T-cell and adult stem cell technologies. The company's products include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS. The adult stem cell technology is in the preclinical development stage. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.75 |
| Volume | 148792 |
| Volume Avg | 79787 |
| 52 Week High | 2.30 |
| 52 Week Low | 0.80 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.27 |
| EPS change Q/Q | -20% |
| EPS change Q/Q Yr ago | -33.33% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -76.67% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |